Who is sponsoring NCT06758583?

NCT06758583 is sponsored by Zealand Pharma.

What condition does NCT06758583 study?

NCT06758583 studies Overweight and Obesity.

What drugs are being tested in NCT06758583?

Interventions: Dapiglutide 7.5 mg.

What is the status of NCT06758583?

NCT06758583 is currently COMPLETED.

Last reviewed 2025-05-06 · How we verify

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

NCT06758583 PHASE1 COMPLETED

This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL. The trial will be conducted in participants with a BMI ≥ 27.0 kg/m2.

Details

Lead sponsor	Zealand Pharma
Phase	PHASE1
Status	COMPLETED
Enrolment	30
Start date	Mon Dec 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Apr 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Overweight and Obesity

Interventions

Dapiglutide 7.5 mg

Countries

Germany